← DOOMRADAR

markets · Published brief

BioNTech shares fall 9% after colorectal cancer trial is discontinued

BioNTech shares dropped 9% after the company discontinued a colorectal cancer program. The move represents a significant setback for the drug developer.

By DoomRadar · Published on DoomRadar .

Why it matters

The trial halt could affect investor confidence and expectations for BioNTech's oncology pipeline.

Related source links

These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.

No matching source link is available in the saved records for this brief.

AI-assisted, source-based analysis. Methodology · Report a correction

Connected by topic or specific details. Dates below are publication dates; the articles may describe separate events.

MORE RECENT READING

Amgen shares fall after trial failure clouds cholesterol-drug prospects

Amgen shares fell 10% after a Novartis trial failure raised concerns about the cholesterol-drug class; Novartis shares reportedly fell 14%. The development affected major pharmaceutical companies and investor expectations.

Related details in the reporting

MORE RECENT READING

Novartis shares fall after pelacarsen trial failure

Novartis shares fell 1.9% after failure of the pelacarsen trial erased CHF4.9 billion in market value. The setback affects development of the company's cardiovascular treatment candidate.

Related details in the reporting

More in Markets & economy → · Browse the event archive →